{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:20:20Z","timestamp":1788931220545,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T00:00:00Z","timestamp":1550534400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12902-019-0335-x","type":"journal-article","created":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T15:08:09Z","timestamp":1550588889000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Late-onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report"],"prefix":"10.1186","volume":"19","author":[{"given":"Ayumu","family":"Takeno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miwa","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayuri","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ippei","family":"Kanazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakae","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshitsugu","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,19]]},"reference":[{"issue":"8","key":"335_CR1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323.","journal-title":"N Engl J Med"},{"issue":"26","key":"335_CR2","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443\u201354.","journal-title":"N Engl J Med"},{"issue":"5","key":"335_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0013","volume":"4","author":"CS Fuchs","year":"2018","unstructured":"Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, et al. Safety and efficacy of Pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction Cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4(5):e180013.","journal-title":"JAMA Oncol"},{"issue":"5","key":"335_CR4","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1200\/JCO.2012.44.6112","volume":"31","author":"A Ribas","year":"2013","unstructured":"Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013;31(5):616\u201322.","journal-title":"J Clin Oncol"},{"issue":"21","key":"335_CR5","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","volume":"30","author":"JS Weber","year":"2012","unstructured":"Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691\u20137.","journal-title":"J Clin Oncol"},{"issue":"7","key":"335_CR6","first-page":"662","volume":"14","author":"KC Kahler","year":"2016","unstructured":"Kahler KC, Hassel JC, Heinzerling L, Loquai C, Mossner R, Ugurel S, Zimmer L, Gutzmer R. Cutaneous side effects Committee of the Work Group Dermatological O: management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma. J Dtsch Dermatol Ges. 2016;14(7):662\u201381.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"6","key":"335_CR7","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/jjco\/hyw036","volume":"46","author":"R Tanaka","year":"2016","unstructured":"Tanaka R, Fujisawa Y, Maruyama H, Nakamura Y, Yoshino K, Ohtsuka M, Fujimoto M. Nivolumab-induced thyroid dysfunction. Jpn J Clin Oncol. 2016;46(6):575\u20139.","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"335_CR8","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/1346-8138.13028","volume":"43","author":"T Narita","year":"2016","unstructured":"Narita T, Oiso N, Taketomo Y, Okahashi K, Yamauchi K, Sato M, Uchida S, Matsuda H, Kawada A. Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab. J Dermatol. 2016;43(2):210\u20134.","journal-title":"J Dermatol"},{"issue":"4","key":"335_CR9","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1210\/jc.2012-4075","volume":"98","author":"SM Corsello","year":"2013","unstructured":"Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab. 2013;98(4):1361\u201375.","journal-title":"J Clin Endocrinol Metab"},{"key":"335_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40842-016-0034-8","volume":"2","author":"A Faje","year":"2016","unstructured":"Faje A. Hypophysitis: evaluation and management. Clin Diabetes Endocrinol. 2016;2:15.","journal-title":"Clin Diabetes Endocrinol"},{"issue":"4","key":"335_CR11","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2337\/dc14-2349","volume":"38","author":"J Hughes","year":"2015","unstructured":"Hughes J, Vudattu N, Sznol M, Gettinger S, Kluger H, Lupsa B, Herold KC. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care. 2015;38(4):e55\u20137.","journal-title":"Diabetes Care"},{"issue":"4","key":"335_CR12","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320\u201330.","journal-title":"N Engl J Med"},{"issue":"9","key":"335_CR13","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.2337\/dc15-0889","volume":"38","author":"M Mellati","year":"2015","unstructured":"Mellati M, Eaton KD, Brooks-Worrell BM, Hagopian WA, Martins R, Palmer JP, Hirsch IB. Anti-PD-1 and anti-PDL-1 monoclonal antibodies causing type 1 diabetes. Diabetes Care. 2015;38(9):e137\u20138.","journal-title":"Diabetes Care"},{"issue":"6","key":"335_CR14","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1111\/jdi.12531","volume":"7","author":"M Okamoto","year":"2016","unstructured":"Okamoto M, Okamoto M, Gotoh K, Masaki T, Ozeki Y, Ando H, Anai M, Sato A, Yoshida Y, Ueda S, et al. Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy. J Diabetes Investig. 2016;7(6):915\u20138.","journal-title":"J Diabetes Investig"},{"key":"335_CR15","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/j.1600-065X.2008.00662.x","volume":"224","author":"BT Fife","year":"2008","unstructured":"Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev. 2008;224:166\u201382.","journal-title":"Immunol Rev"},{"issue":"11","key":"335_CR16","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1210\/jc.2014-2306","volume":"99","author":"AT Faje","year":"2014","unstructured":"Faje AT, Sullivan R, Lawrence D, Tritos NA, Fadden R, Klibanski A, Nachtigall L. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014;99(11):4078\u201385.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"335_CR17","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1530\/EJE-14-0845","volume":"172","author":"F Albarel","year":"2015","unstructured":"Albarel F, Gaudy C, Castinetti F, Carre T, Morange I, Conte-Devolx B, Grob JJ, Brue T. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol. 2015;172(2):195\u2013204.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"335_CR18","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1158\/1078-0432.CCR-14-2353","volume":"21","author":"L Min","year":"2015","unstructured":"Min L, Hodi FS, Giobbie-Hurder A, Ott PA, Luke JJ, Donahue H, Davis M, Carroll RS, Kaiser UB. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res. 2015;21(4):749\u201355.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"335_CR19","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1507\/endocrj.EJ16-0161","volume":"63","author":"Y Okano","year":"2016","unstructured":"Okano Y, Satoh T, Horiguchi K, Toyoda M, Osaki A, Matsumoto S, Tomaru T, Nakajima Y, Ishii S, Ozawa A, et al. Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma. Endocr J. 2016;63(10):905\u201312.","journal-title":"Endocr J"},{"issue":"3","key":"335_CR20","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1111\/1346-8138.13532","volume":"44","author":"T Fujimura","year":"2017","unstructured":"Fujimura T, Kambayashi Y, Furudate S, Kakizaki A, Hidaka T, Haga T, Hashimoto A, Morimoto R, Aiba S. Isolated adrenocorticotropic hormone deficiency possibly caused by nivolumab in a metastatic melanoma patient. J Dermatol. 2017;44(3):e13\u20134.","journal-title":"J Dermatol"},{"issue":"1","key":"335_CR21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/1346-8138.13437","volume":"44","author":"M Ishikawa","year":"2017","unstructured":"Ishikawa M, Oashi K. Case of hypophysitis caused by nivolumab. J Dermatol. 2017;44(1):109\u201310.","journal-title":"J Dermatol"},{"issue":"5","key":"335_CR22","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1093\/jjco\/hyx018","volume":"47","author":"K Kitajima","year":"2017","unstructured":"Kitajima K, Ashida K, Wada N, Suetsugu R, Takeichi Y, Sakamoto S, Uchi H, Matsushima T, Shiratsuchi M, Ohnaka K, et al. Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumab. Jpn J Clin Oncol. 2017;47(5):463\u20136.","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"335_CR23","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1507\/endocrj.EJ16-0596","volume":"64","author":"KY Cho","year":"2017","unstructured":"Cho KY, Miyoshi H, Nakamura A, Kurita T, Atsumi T. Hyponatremia can be a powerful predictor of the development of isolated ACTH deficiency associated with nivolumab treatment [letter to the editor]. Endocr J. 2017;64(2):235\u20136.","journal-title":"Endocr J"},{"issue":"4","key":"335_CR24","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1111\/1346-8138.13571","volume":"44","author":"A Narahira","year":"2017","unstructured":"Narahira A, Yanagi T, Cho KY, Nakamura A, Miyoshi H, Hata H, Imafuku K, Kitamura S, Shimizu H. Isolated adrenocorticotropic hormone deficiency associated with nivolumab therapy. J Dermatol. 2017;44(4):e70.","journal-title":"J Dermatol"},{"issue":"10","key":"335_CR25","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","volume":"32","author":"SL Topalian","year":"2014","unstructured":"Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020\u201330.","journal-title":"J Clin Oncol"},{"key":"335_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.lungcan.2017.02.013","volume":"108","author":"H Kimura","year":"2017","unstructured":"Kimura H, Sone T, Murata A, Koba H, Tambo Y, Hara J, Abo M, Kasahara K. Long-lasting shrinkage in tumor mass after discontinuation of nivolumab treatment. Lung Cancer. 2017;108:7\u20138.","journal-title":"Lung Cancer"},{"issue":"5","key":"335_CR27","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/1346-8138.13486","volume":"44","author":"Y Teramoto","year":"2017","unstructured":"Teramoto Y, Nakamura Y, Asami Y, Imamura T, Takahira S, Nemoto M, Sakai G, Shimada A, Noda M, Yamamoto A. Case of type 1 diabetes associated with less-dose nivolumab therapy in a melanoma patient. J Dermatol. 2017;44(5):605\u20136.","journal-title":"J Dermatol"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-019-0335-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12902-019-0335-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-019-0335-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T03:11:39Z","timestamp":1662952299000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-019-0335-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,19]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["335"],"URL":"https:\/\/doi.org\/10.1186\/s12902-019-0335-x","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,19]]},"assertion":[{"value":"9 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of this case report was obtained from the family of the patient after her death. A copy of the consent form is available for review by the editor of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"25"}}